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Abstract
Objective: The objective of this selective EBM review is to determine whether or not the use of
antidepressants improves the quality of life and decreases the severity of symptoms in patients
with IBS.
Study Design: Review of three English language, double-blind, randomized controlled trials
published in 2009.
Data sources: Randomized controlled trials comparing the use of three different antidepressants
to a controlled placebo were found on PubMed, OVID and the Cochrane database.
Outcome(s) Measured: Primary end point was overall bowel symptom score at the end of
twelve weeks. Secondary end points include individual BSS for each irritable bowel syndrome
subset, constipation, pain, or discomfort. Other secondary end points assessed adequate relief of
symptoms, IBS-quality of life, and rectal sensitivity. Outcomes were measured through the use
of questionnaires.
Results: Three randomized controlled trials were included in this review. The study by AbdulBaki H. indicated that imipramine was superior to treating IBS when compared to placebo,
making this the only therapy evaluated in this review to be effective. Study by Ladabaum U.
indicated that citalopram was less effective than placebo. Study by Saito Y. determined that St.
John’s Wort was less effective than placebo in decreasing symptoms of IBS.
Conclusions: The results of the study using imipramine concluded that the drug was effective in
reducing symptoms and improving quality of life for patients with IBS. The other two studies
concluded that the therapy drugs were less effective than the placebo in treating symptoms of
IBS. The population studied in some of the studies was not very large and one study had a
majority of females which are factors that should be changed in future studies.
Key Words: Irritable bowel syndrome, antidepressants, quality of life
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Introduction
Irritable bowel syndrome (IBS) is a condition that causes abdominal pain which affects
approximately 10-15% of the adult population.1 IBS is defined by the Rome II criteria and is
characterized by constipation, diarrhea, or an alternation of the two. It is also defined by the
presence of abdominal pain, fullness, bloating, and relief after defecation present for at least
three days per month for the past three consecutive months.1 In recent years, there has been a
dramatic rise of the diagnosis of IBS due to increased awareness of the condition. While it is
estimated that 10-15% of the adult population is affected by IBS, only 50% of patients with
symptoms search for aid. 2
The epidemiology of the condition may depend on where the patient lives or the regional
culture in regards to healthcare. For example, in the United States, women are more likely to be
effected or report symptoms. However, men are more likely to be effected in India and Sri
Lanka.2 The pathophysiology of IBS is still unclear, which is why there is so much research
being done for treatment options.1This paper evaluates three RCTs studying the effectiveness of
antidepressants in decreasing symptoms and improving quality of life for patients with IBS.
The total cost for IBS patients in the United States for health care 21.5 billion dollars a
year.3 The cost in the first year of healthcare for IBS diagnosis is $4,044 and the sum of all
patients lose 205 million dollars from lost work days due to either the condition itself or days
spent seeking healthcare.3 There was an average of approximately 3.65 million visits a year
between 1998-2000 for patients with IBS.3 There is not much that is known for certain about the
condition. In recent studies, it was found that up to 80% of patients with IBS have an associated
psychiatric etiology. 1There are many theories regarding what initiates IBS and how the
condition produces symptoms, however, the exact physiology of the condition is unknown. Some
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hypotheses believe that there may be disturbance of motility, gastrointestinal (GI) changes from
infection, or altered perception of pressure in the GI tract.1
Researchers have determined that the pathophysiology is based on the individual. In
some individuals, it has been found that there is increased activity of the prefrontal lobe with
colonic activity. 1Therefore, indicating that these patients may have increased sensitivity and
awareness of abdominal discomfort. In other studies it was found that serotonin plays a large
role in symptomatology of IBS. Serotonin is released into the gut and stimulates peristalsis. 1It
has been found that patients with diarrhea symptoms do not reabsorb the serotonin from the gut
properly, therefore over stimulating the intestines and producing diarrhea.1
Treatment methods depend on the symptoms of patients. Physicians often recommend to
patients beginning treatment with an alteration of diet. For example, food items such as coffee,
legumes, and artificial sweeteners have been found to aggravate symptoms, particularly in
patients with diarrhea symptoms.1For patients with constipation symptoms, patients are
recommended to increase fiber to 30g a day and consume probiotics.

1,4

Other non-

pharmacologic treatments involve stress management or hypnotherapy. 1
Pharmacologic treatment approaches IBS from different aspects of the pathophysiology
behind the condition. For example, anti-diarrheal medications are the first line drugs of choice
for patients with diarrhea. 1 Anti-spasmodic use is still somewhat controversial. It has been found
that this class of drugs may help to alleviate pain by decreasing the amount of intestinal
cramps.1This paper evaluates three randomized controlled trials(RCT) for the effectiveness of
antidepressant use in decreasing symptoms and improving quality of life for patients with IBS.

Objective
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The objective of this selective EBM review is to determine whether or not the use of
antidepressants decreases symptoms and improves the quality of life in patients with IBS.
Methods
The criteria for selection involved a population of men and women between the ages of
18 and 75 who meet the Rome II criteria of IBS. The intervention used was three different
antidepressants including imipramine, citalopram, and St. John’s Wort. The experimental group
was compared to an identical placebo given to the control group. The outcomes measured were
improvement of IBS symptoms, in regards to frequency and severity, and increased quality of
life. The types of studies used were RCTs.
Key words used to find literature were irritable bowel syndrome, antidepressant use, and
quality of life. All articles were published in the English language. All articles were published in
peer review journals after the year 2009 and there were at least three articles published after the
meta-analysis which was published in 2008. Research for articles was completed by me using
PubMed and OVID after using the Cochrane database. Articles were selected based on relevance
to the subject of interest and the outcomes measured in relationship to the patient, or a POEM.
All articles chosen were randomized, controlled double blind studies. Articles were excluded in
the studies if the patients were under 18 years old or if the results were not measured based on
patient outcome. The statistics that were used in the articles were confidence interval(CI), p
values, relative risk reduction(RRR), absolute risk reduction(ARR), numbers needed to treat
(NNT), numbers needed to harm (NNH). Table 1 demonstrates the demographics included in the
studies.
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Table 1 - Demographics & Characteristics of included studies
Study
Type # of Age
Inclusion
Exclusion
w/d intervention
pts
Saito et
RCT 70
18-70 Pts that meet
Concurrent GI diagnosis; 10
Double blind
al., 2010
the Rome II
symptoms of severe
Randomized
criteria for IBS depression; MR; past or
450 mg BID
current Hx of psychotic
St. John’s
d/o; current use of
Wort vs.
mood/pain or symptom
placebo.
altering meds- planned
surgery during trial;
allergy to St. John’s
wort; any current chronic
or acute diseases; ETOH
abuse; professional
drivers or operators of
heavy equipment; major
CV events in the last 6
mo; use of IBS drugs in
the past 30 day
AbdulRCT 107 >18
Pts that meet
< 18 y/o; allergy to
51
Double blind
Bakiet
y/o
the rome II
imipramine; Hx of
randomized,
al., 2009
criteria for IBS melena/hematochezia/wt
25 mg tablet
and have an
loss/cardiac arrhythmias;
of imipramine
unsatisfactory
any use drugs of drugs
vs identical
response to 1+ that could change bowel
placebo
prescription
habits; lactose
antispasmodics intolerance; use of
available on
antidepressants; clinical
the Lebanese
depression
market
Ladabau RCT 54
18-75 Pts that meet
Depression or use of
9
Double blind
m et al. ,
y/o
the rome II
antidepressants;
randomized,
2010
criteria for
pregnancy; use of IBS
20 mg
IBS;good
medication/antispansmod
citalopram vs
health; normal ics/anticholinergics;
identical
sigmoidoscopy chronic pain meds using
placebo
/colonoscopy
opiates; prior rectal/colon
w/in 5 yrs;
surgery; major organ
normal CBC
disease
and TFS
Information from Saito YA., Abdul-Baki H., and Ladabaum U. was used in the above
table.
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Outcomes measured
Outcomes measured were based on patient-oriented problems. In the study using St.
John’s Wort(SJW), outcomes were measured using a bowel symptoms score (BSS) and IBS
quality of life (IBS-QoL). 5 The BSS was based on pain, bloating, constipation and diarrhea. The
IBS-QoL has thirty-four questions assessing quality of life.5 The imipramine study used the IBSQoL, as well as, a SF-36 questionnaire.6 The citalopram study used Beck’s Depression Inventory,
daily symptom scoring on a scale from 1-10, IBS-QoL, and a barostat study to assess outcomes.7
Results
The results were presented in dichotomous data for all three articles. The study using SJW
randomly assigned participants to a group using 450 mg of SJW by mouth twice a day or an
identical placebo for twelve weeks.5 Patients were asked to evaluate their symptoms on a BSS
and IBS-QoL prior to the start of the study and again at twelve and twenty-four weeks after the
start of the study. The study also assessed depression symptoms using center for epidemiological
studies depression scale (CES-D).5
In Saito et al., the mean change from the baseline BSS score decreased in both groups.
However, it was found that the BSS in SJW was seventy-six compared to forty-four in the
placebo group, indicating that the placebo group had a better outcome.5At twelve weeks, “51%
of the study drug group compared to 54% of the placebo group felt that the drug had helped
decrease the symptoms”. 5 The P value was .03(Table 2), the relative benefit increase (RBI) was .055, the absolute benefit increase (ABI) was -.03 and the number needed to treat (NNT) was 34. 5 The negative NNT indicates that for every thirty-four patients who were treated with SJW,
there would be one fewer patient that would have decreased symptoms or increased QoL than if
they had been treated with placebo.
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The study using imipramine randomly assigned participants to a group using 25 mg of the
drug by mouth once a day before bedtime or identical placebo for twelve weeks. 6 Patients were
asked on week four, eight and twelve if they “had significant improvement in symptoms since
the start of the study drug.” 6 At twelve weeks patients were asked to assess the QoL based on a
SF-36 questionnaire. At week 16 a follow-up questionnaire was given to evaluate overall
symptoms.6 In Abdul-Baki et al., “80.6% of the imipramine group compared to 48.0% of the
placebo group” reported relief in IBS symptoms. The p-value, per protocol, was .053(Table 2),
the RBI was .68, the ABI was .33, and the NNT was 4. This indicates that for every four patients
treated with imipramine one more patient had decreased symptoms or improved QoL than if they
had been treated with the placebo.
In the study using citalopram, patients were randomly assigned to a group using 20 mg of the
drug by mouth for the first four weeks or a group using identical placebo.7 After the first four
weeks, patients were instructed to take two tablets for another four weeks, resulting in either 40
mg of citalopram therapy or two tablets of placebo a day.7 If patients experienced side effects
while on two tablet therapy they were instructed to decrease dose to one tablet a day. Prior to the
start of the study, participants filled out the Beck’s Depression Inventory, daily symptom scoring
on a scale from 1-10, IBS-QoL, and a barostat study. 7
Throughout the study, questionnaires were given weekly to evaluate the symptoms on a scale
from 1-10 and whether or not adequate relief had been achieved. At week eight of the study,
participants completed a second IBS-QoL and barostat study.7Ladabaum U. et al. demonstrated
that “44% in the citalopram group compared to 56% in the placebo group showed
improvement.”7The P value was .59(Table 2) and there was a 95% CI .61-1.04, indicating that
the treatment effect is precise. The RBI was - .214, the ABI was -.12, and the NNT was -9.7 The
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negative NNT indicates that for every nine patients who were treated with SJW, there would be
one fewer patient that would have decreased symptoms or increased QoL than if they had been
treated with placebo.
Table 2 Comparison of study results 5,6,7
Study
Response
Response
RBI
ABI
NNT
P-value
in the study in the
group
control
group
Ladabaum 44%
56%
-0.241
-0.12
-9
0.59
(2010)
Saito(2010) 51%
54%
-0.055
-0.03
-34
0.03
Abdul80.6%
48.0%
0.68
.129
4
<0.01
Baki(2009)
Information from Saito YA., Abdul-Baki H., and Ladabaum U. was used in the above
table.
In the studies using SJW and citalopram the NNT was a negative value while the study
using imipramine demonstrated a positive value for NNT. Of the three studies used, imipramine
was the only drug that was found to improve symptoms and IBS-QoL. There were a high
percentage of dropouts in the imipramine study. In the imipramine and placebo group, 14/59 and
6/48, respectively, dropped out due to side effects. 6 Three of the fourteen participants that
dropped out on the imipramine group due to adverse side effects reported sleep disturbance,
making this the most common side effect. A higher percentage of patients taking imipramine
experienced adverse effects compared to placebo, “25% and 12.5%” respectively. 6 This indicates
that the relative risk increase is 1.03, the absolute risk increase is .129, and the number needed to
harm is 8.6 This indicates that for every eight people that are treated with imipramine, one person
experiences an adverse effect.
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Table 3-Reason for dropout in both study groups6
Imipramine (n= 59)
Placebo (n=48)
Total dropouts
28 (47.5%)
23(47.9%)
Premature withdrawl
8 (13.6%)
14 (29.2%)
Lost to follow-up
3 (5.1%)
3 (6.3%)
Protocol violation
3
0
Side effects
14 (23.7%)
6 (12.5%)
This table comes directly from Abdul-Baki H. et al.

P-value
NS
<0.05
NS
NS
0.094

Discussion
The RCT (Saito Y. et al.) assessing the efficacy of SJW to reduce IBS symptoms, determined
that SJW was less effective than the placebo. The BSS, AR, and IBS-QoL measured all indicated
similar results. There are very few well designed studies evaluating the use of herbal and
alternative medicine. For example, there are no studies indicating what the appropriate dose of
SJW is, therefore, producing an inconsistency in the study. 5 The population of this study may
alter the results. The participants included were from a smaller area with both mild IBS
symptoms and mood disorders. Patients with severe mood disorders were excluded from the
study. 5 Also, this study is limited due the evaluation of all IBS subtypes. In theory, one subset
may benefit over another but that issue was not addressed. Another limitation to this study is the
inclusion of a majority females compared to male participants. 5
In the RCT (Abdul-Baki H. et al.) assessing the efficacy of imipramine use for IBS
symptoms, it was determined that the drug may provide relief. 6 The SF 36 assessment
completed after the study indicated a rise in QoL 6 Limitations to the study include a lack of
evaluation of baseline psychiatric illness prior to the start of the study. 6 Another issue in the
study that limits the results is the possibility of “unblinding due to the presence of anticholinergic
effects.” 6 The high drop-out rate is also a limitation to the study. Additionally, there is a large
chance of a non-adherence to the medication throughout the trial. 6
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In the RCT (Ladabaum U.) assessing the efficacy of citalopram use for IBS symptoms, it was
determined that the drug was less effective than the placebo. A stipulation of the study is that the
drug only evaluates non-depressed patients, which may affect the results reported. 7 One
limitation to the study is the small sample size. Another limitation is the “possibility of
unblinding due to side effects.” 7
Conclusion
Evidence regarding anti-depressant therapy for improving IBS-QoL and decreasing IBS
symptoms is conflicting. Of the three RCTs used in this systematic review, only one of them
concluded that the drug was effective for improving symptoms of IBS. The study using SJW
stated that the therapy was less effective than the placebo. However, the study also stated that
there are very few well-designed studies testing the efficacy of herbs and alternative treatments. 5
The study using citalopram also concluded that the drug was less effective than placebo for
treatment of IBS symptoms. 7 The study using imipramine was the only therapy found to be
effective. Lack of a specific antidepressant or class of antidepressants is a flaw in research for
this systematic review. For further research, one would isolate the therapy that has been found to
be effective and expand upon that. For example, sample size of the study can be increased to
assess a larger population which would provide a better representation of a typical population.
Additionally, it reasonable to design future studies using drugs with similar mechanism of action
to that of imipramine, such as other tricyclic antidepressants. Further research is necessary to
conclude whether or not antidepressant therapy is effective in decreasing symptoms and
improving QoL in patients with IBS.
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